Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J QUIN

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Breast Cancer Research and Treatment|June 1, 1995
CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancerP L Devine, M A Duroux, R J Quin, et al.
Disease Markers|July 31, 1999
Serum mucin antigen (CASA) as a marker of amiodarone-induced pulmonary toxicityP L Devine, W J Siebert, S L Morton, et al.
Journal of Leukocyte Biology|October 16, 2002
MUC1 epithelial mucin (CD227) is expressed by activated dendritic cellsM Wykes, K P A MacDonald, M Tran, et al.
The British Journal of Ophthalmology|November 6, 2015
Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trialHemal Mehta, Samantha Fraser-Bell, Aaron Yeung, et al.
Ophthalmology|August 27, 2014
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX studyMark C Gillies, Lyndell L Lim, Anna Campain, et al.
Journal of Medicinal Chemistry|August 6, 1993
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996)I Sircar, J C Hodges, J Quin, et al.
Journal of Medicinal Chemistry|September 15, 1995
Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonistsJ J Edmunds, S Klutchko, J M Hamby, et al.
Journal of Medicinal Chemistry|January 1, 1992
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitorsA M Doherty, I Sircar, B E Kornberg, et al.
Journal of Medicinal Chemistry|November 1, 1991
Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtypeC J Blankley, J C Hodges, S R Klutchko, et al.
Human Mutation|March 24, 2009
Planning the human variome project: the Spain reportJim Kaput, Richard G H Cotton, Lauren Hardman, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Breast Cancer Research and Treatment|June 1, 1995
CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancerP L Devine, M A Duroux, R J Quin, et al.
Disease Markers|July 31, 1999
Serum mucin antigen (CASA) as a marker of amiodarone-induced pulmonary toxicityP L Devine, W J Siebert, S L Morton, et al.
Journal of Leukocyte Biology|October 16, 2002
MUC1 epithelial mucin (CD227) is expressed by activated dendritic cellsM Wykes, K P A MacDonald, M Tran, et al.
The British Journal of Ophthalmology|November 6, 2015
Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trialHemal Mehta, Samantha Fraser-Bell, Aaron Yeung, et al.
Ophthalmology|August 27, 2014
A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX studyMark C Gillies, Lyndell L Lim, Anna Campain, et al.
Journal of Medicinal Chemistry|August 6, 1993
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996)I Sircar, J C Hodges, J Quin, et al.
Journal of Medicinal Chemistry|September 15, 1995
Derivatives of 5-[[1-(4'-carboxybenzyl)imidazolyl]methylidene]hydantoins as orally active angiotensin II receptor antagonistsJ J Edmunds, S Klutchko, J M Hamby, et al.
Journal of Medicinal Chemistry|January 1, 1992
Design and synthesis of potent, selective, and orally active fluorine-containing renin inhibitorsA M Doherty, I Sircar, B E Kornberg, et al.
Journal of Medicinal Chemistry|November 1, 1991
Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtypeC J Blankley, J C Hodges, S R Klutchko, et al.
Human Mutation|March 24, 2009
Planning the human variome project: the Spain reportJim Kaput, Richard G H Cotton, Lauren Hardman, et al.
Pageof 4